You are correct, the vitrocard data does not include the placebo.
This new trial is very targeted and an interesting idea. They have chosen those who showed the best result in the past trial (Margolis 1 categorised ulcers).
One problem with small trial statistics, is statistically speaking a sub group will probably always do better. But the Margolis1's showed such a good improvement that it is likely not just accidental.
The data is seen and analysed after the last patient completes the study. This keeps it all blind.
FTT Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held